[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","bm0lazfel11dmzrnk90o8j9on","revision",2,"title","Evogene 将急性移植物抗宿主病列为内部 AI 药物发现项目的目标适应症","originalTitle","6-K - Evogene Ltd. (0001574565) (Filer)","summary","Evogene 于 10 月 28 日宣布，将急性移植物抗宿主病（aGVHD）确定为其内部 AI 驱动药物发现项目的目标适应症。相关公告作为附件纳入公司提交的 Form 6-K。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-28T12:30:08.000Z","discoveredAt","2026-10-29T03:37:08.312Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",29,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f2OwBMauR1jQ",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","c4d19446-b223-4215-aca9-4ad69da9a0c6","Evogene将aGVHD列为内部AI药物发现目标",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES\nAND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant’s\nName into English)

13 Gad Feinstein Street, Park Rehovot

Rehovot 7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant\nfiles or will file annual reports under cover of Form 20-F or Form 40-F.

Form\n20-F ☒ \nForm 40-F ☐

CONTENTS

On October 28, 2026, Evogene\nissued a press release announcing Acute Graft-Versus-Host Disease (aGVHD) as the target indication for its internal AI-driven drug discovery\nprogram. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Exhibits

\n \n \n \n \n \n \n \n \n

Exhibit No.
99.1		Press Release: Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

Incorporation by Reference

The contents of Exhibit\n99.1 to this Form 6-K, excluding the statements of Head of Tumor Immunology at University Medical Center Freiburg, the Director of the\nAdult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute and the Chief Development Officer of Evogene, are incorporated\nby reference in the registration statements on Form F-3 (Securities and Exchange Commission File No.’s 333-277565\nand 333-294650), and Form S-8 (SEC File No.’s 333-193788, 333-201443, 333-203856, 333-259215, 333-286197 and 333-294648)\nof Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or\nreports subsequently filed or furnished.

Signature

Pursuant to the requirements of the Securities\nExchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

\n \n \n \n \n

\n
\n
\nDate: October 28, 2026

EVOGENE LTD.
\n(Registrant)
\n
\nBy: /s/ Ofer Haviv
\nOfer Haviv
\nChief Executive Officer

","zhKind","complete","EVGN","公司与财报","AI","aihot","/items/bm0lazfel11dmzrnk90o8j9on","https://www.sec.gov/Archives/edgar/data/1574565/000117891326004871/0001178913-26-004871-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1793664000&sig=2a69d6ab08599a1a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1793664000&sig=c72c622a1dc90100 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1793664000&sig=c831626a2a361459 96w","changelogVersion","2026-10-01T08:00"]